Literature DB >> 10654614

Recent developments in the virus therapy of cancer.

T A Steele1.   

Abstract

Cancer is one of the leading causes of death in the United States. Although there has been significant progress in the areas of cancer etiology, diagnostic techniques, and cancer prevention, adequate therapeutic approaches for many cancers have lagged behind. One promising line of investigation is the virus therapy of cancer. This approach entails the use of viruses, such as retroviruses, adenovirus, and vaccinia virus, to modify tumor cells so that they become more susceptible to being killed by the host immune response, chemotherapeutic agents, or programmed cell death. This review discusses recent advances in the virus therapy of cancer from both basic science and clinical perspectives. Given the potential of viruses to kill tumor cells directly or transduce desired gene products to allow a vigorous host antitumor immune response, the virus therapy of cancer holds great promise in the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10654614     DOI: 10.1046/j.1525-1373.2000.22317.x

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


  3 in total

1.  Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease.

Authors:  Marilyn Fernandez; Mercedes Porosnicu; Dubravka Markovic; Glen N Barber
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

2.  Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis.

Authors:  S Balachandran; M Porosnicu; G N Barber
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

3.  Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity.

Authors:  Masatsugu Obuchi; Marilyn Fernandez; Glen N Barber
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.